Search
-
Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19
(European Radiology, 2023-07-05)Article de revueOpen access -
Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo
(Cell Reports. vol. 42, n° 9, pp. 113101, 2023-09-26)Article de revueOpen access -
Impact of non-pharmaceutical interventions, weather, vaccination, and variants on COVID-19 transmission across departments in France
(BMC Infectious Diseases. vol. 23, 2023-03-30)Article de revueOpen access -
Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
(NPJ vaccines. vol. 8, n° 1, pp. 174, 2023-11-08)Article de revueOpen access -
Evaluating the Use of Generalized Dynamic Weighted Ordinary Least Squares for Individualized Hiv Treatment Strategies
(Annals of Applied Statistics. vol. 17, n° 3, pp. 2432-2451, 2023-09)Article de revueOpen access -
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone
(Lancet Global Health. vol. 11, n° 11, pp. e1743-e1752, 2023-11)Article de revueOpen access -
Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health
(BMJ Evidence-Based Medicine, 2023-02-14)Article de revueOpen access -
Assessment of circulating blood lymphocytes in adult patients on rituximab to treat immune thrombocytopenia: Circulating number of NK cells is associated with the response at 6 months.
(British Journal of Haematology, 2023-04-20)Article de revueOpen access